For founders and early biotech teams

Take any drug program to its next milestone on one platform.

Start from a scientific hypothesis or an existing asset. Praxis works out the next step, finds who can do the work, and prepares the financing — built on real drug-development expertise.

Apply for the first cohort.

Applications are open for the first 20 biotech companies. Tell us where you are and we will reach out.

Where are you starting from?

Confidential. No data leaves this form but what you type in it.

Watch a program move

Praxis knows the next step.

Ask about a disease and Praxis starts where a drug developer would: the landscape, then the target, then the decision. Once you call it, the work is planned and the providers are found.

  1. TriggerNew programMASH · compensated cirrhosis
  2. ResearchMap the landscapeStandard of care · trials · white space
  3. EvidenceEvaluate targetTHRB · 5 evidence lines graded
  4. GateGo / no-goYour call, with the case for each
  5. BranchParkRevisit when evidence changes
  6. PlanPlan experiments6 work packages · done-when criteria
  7. ProvidersMatch providersCROs · CDMOs · labs

Every claim traced to its source

  • ClinicalTrials.gov
  • FDA
  • Open Targets
  • Europe PMC
  • ChEMBL
  • NIH

One platform, every next step

Run your program like a full biotech team.

Praxis is proactive: it knows what a program needs at each stage and prepares the work, so a small team can move like a large one.

  • No more stitching together spreadsheets, consultants, and databases
  • Decisions grounded in cited clinical and scientific evidence
  • Providers, grants, and investors matched to your stage
Apply for early access

Everything a biotech needs, in one platform.

F2–F3F4Decomp.
Approved drugs White space

The landscape in minutes

Standard of care, patient populations, and the clinical white space no approved drug covers — each figure with its source.

ResmetiromTHRBMet
SemaglutideGLP1RMet
CilofexorFXRMissed

Know what you have to beat

Competing drugs, their mechanisms, and every trial that has read out, with the result as posted and whether it met its endpoint.

Clinical
Literature
Animal models
Human genetics
Go · validated in patients

Go or no-go, with the evidence

Human genetics, clinical, animal models, and literature graded by strength — then your call, with what would make the case stronger.

  • Recombinant proteinPurity ≥ 90%
  • Biochemical assayZ′ ≥ 0.5
  • Hit finding≥ 3 hit series

Experiments with a finish line

Praxis turns a hypothesis into work packages, each with the criteria that mark it done and the evidence it has to produce.

  • LabValidate mechanismShortlisted
  • Tox CROGLP toxicologyQuote requested
  • CDMOClinical materialMatched

Find who can do the work

A lab to validate the mechanism, a CRO for toxicology, a manufacturer for clinical material — matched, shortlisted, and briefed.

NIH SBIR · Phase IEligible
Venture capitalDeck outline
Strategic partners Matching

Finance the next stage

Research grants, venture capital, and strategic partners matched to your stage, with eligibility checked and applications drafted.

Apply for early access

Build a biotech with a smaller team.

Coordinate specialized expertise and infrastructure as you need it, instead of hiring for all of it up front.

Apply for early access

What it looks like in practice

From one question to a funded plan.

Example program · MASH

1 question → 6 work packages

“I want to start a drug development program in MASH.” Praxis mapped the disease, found the white space in compensated cirrhosis with obesity, validated THRB as a target, planned the experiments, and matched an NIH SBIR Phase I grant.

Go
THRB validated in patients
Eligible
NIH SBIR Phase I

Why decisions matter now

23,875

drugs in global development (Citeline, January 2025). GLP-1s were discovered decades ago for diabetes — a business decision took them to obesity. The levers are shifting from novel IP to strategy, clinical development, and asset selection.

1980s
GLP-1 identified
2021
Approved for obesity

Built for how drug development works

Your program, your decisions.

  • Every figure links back to its source.
  • Evidence is graded by strength, and gaps are marked.
  • Go, park, or no-go stays your call.
  • Outreach is drafted, never sent without your approval.
  • Every work package has criteria that mark it done.
  • CROs, CDMOs, and labs filtered by capability and modality.
  • Grant eligibility is checked before you apply.
  • Applications are drafted from the program record, with gaps flagged.
  • Built by a team running its own drug programs on it.
  • Every company in the first cohort is onboarded by our team.

See how Praxis fits your program.

Tell us where you are — a new idea or an existing company — and what you are working on. We are opening Praxis to the first 20 biotech companies.

Apply for early access